Analysts Conflicted on These Healthcare Names: Five Prime Therapeutics (NASDAQ: FPRX), Blueprint Medicines (NASDAQ: BPMC) and Humana Inc (NYSE: HUM)

By Jason Carr

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Five Prime Therapeutics (NASDAQ: FPRX), Blueprint Medicines (NASDAQ: BPMC) and Humana Inc (NYSE: HUM).

Five Prime Therapeutics (NASDAQ: FPRX)

In a report released yesterday, Eun Yang from Jefferies reiterated a Buy rating on Five Prime Therapeutics (NASDAQ: FPRX), with a price target of $55. The company’s shares closed yesterday at $30.60, close to its 52-week low of $27.01.

According to TipRanks.com, Yang is a 3-star analyst with an average return of 1.4% and a 46.8% success rate. Yang covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Achillion Pharmaceuticals, and Ionis Pharmaceuticals Inc.

Five Prime Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $47.

Blueprint Medicines (NASDAQ: BPMC)

In a report issued on June 6, Carmen Augustine from Jefferies reiterated a Buy rating on Blueprint Medicines (NASDAQ: BPMC), with a price target of $52. The company’s shares closed yesterday at $37.63.

Augustine has an average return of 17.4% when recommending Blueprint Medicines.

According to TipRanks.com, Augustine is ranked #2401 out of 4571 analysts.

Currently, the analyst consensus on Blueprint Medicines is Strong Buy and the average price target is $49.25, representing a 30.9% upside.

In a report issued on June 6, Canaccord Genuity also reiterated a Buy rating on the stock with a $52 price target.
Humana Inc (NYSE: HUM)

Jefferies analyst Brian Tanquilut reiterated a Hold rating on Humana Inc (NYSE: HUM) on June 6 and set a price target of $230. The company’s shares closed yesterday at $233.75, close to its 52-week high of $236.35.

According to TipRanks.com, Tanquilut is a 4-star analyst with an average return of 3.4% and a 52.0% success rate. Tanquilut covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Five Star Quality Care, and Quest Diagnostics Inc.

Currently, the analyst consensus on Humana Inc is Moderate Buy and the average price target is $220.75, representing a -5.6% downside.

In a report issued on June 5, RBC Capital also reiterated a Hold rating on the stock with a $214 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.